Presentation is loading. Please wait.

Presentation is loading. Please wait.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Published byJade Powell Modified over 9 years ago

Similar presentations

Presentation on theme: "Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory."— Presentation transcript:

1 Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory Committee 28 February 2014

2 Inactivated Vaccine Serology Studies l Purpose: Evaluation of anti-HA antibody titers to recent viruses as compared to those of the recommended vaccine viruses in children, adults and older adults who had received trivalent or quadrivalent inactivated vaccine (2013-2014 formulation). l Serum samples: Five panels of sera from adults, 5 panels from older adults and 2 panels from pediatric populations were analyzed from trivalent vaccine trials. One panel of sera each from pediatric, adults and older adult was analyzed from a quadrivalent vaccine trial. Sera were collected prior to and 21-28 days post-vaccination. Most of the panels were pre-screened to avoid sera with low antibody titers. l Methods: Hemagglutination inhibition (HI) assays were used to determine HI titers to recent viruses compared to HI titers of the corresponding vaccine virus. A subset of sera was tested by micro-neutralization assay. The serum panels were distributed to and tested in 6 laboratories. 2

3 Serum panels used for studies: seasonal trivalent vaccine AUSTRALIAADULTS OLDER ADULTS A/California/7/2009 (H1N1pdm09) (NYMC X-179A) A/Victoria/361/2011 (H3N2) (IVR-165) B/Hubei-Wujiagang/158/2009 (NYMC BX-39) CHINACHILDREN (4Yr) ADULTS OLDER ADULTS A/Christchurch/16/2010 (H1N1pdm09) (NIB-74xp) A/Texas/50/2012 (H3N2) (NYMC X-223A) B/Massachusetts/2/2012 (NYMC BX-51B) EUROPEADULTS OLDER ADULTS A/Christchurch/16/2010 (H1N1pdm09) (NIB-74xp) A/Texas/50/2012 (H3N2) (NYMC X-223) B/Massachusetts/2/2012 EUROPEADULTS OLDER ADULTS A/Brisbane/10/2010 (H1N1pdm09) A/Texas/50/2012 (H3N2) (NYMC X-223A) B/Massachusetts/2/2012 JAPANADULTS OLDER ADULTS A/California/7/2009 (H1N1pdm09) (NYMC X-179A) A/Texas/50/2012 (H3N2) (NYMC X-223) B/Massachusetts/2/2012 (NYMC BX-51B) USA (CDC contract) CHILDREN (1.7Yr)A/California/7/2009 (H1N1pdm09) (NYMC X-179A) A/Texas/50/2012 (H3N2) (NYMC X-223A) B/Massachusetts/2/2012

4 4 Serum panels used for studies: seasonal quadrivalent vaccine USA (Donated by a US mfr.) CHILDREN (3.5Yr) ADULTS OLDER ADULTS A/California/7/2009 (H1N1pdm09) (NYMC X-179A) A/Texas/50/2012 (H3N2) (NYMC X-223A) B/Massachusetts/2/2012 B/Brisbane/60/2008

5 5 A(H1N1)pdm09 Serology

6 Antigens for serology: A(H1N1)pdm09 REFERENCE VIRUS A/California/7/2009 REPRESENTATIVE CURRENT VIRUSES A/New Hampshire/4/2013Egg A/Mississippi/10/2013Egg A/Massachusetts/15/2013Egg A/Sichuan-Wuhou/2259/2013Egg A/Lisbon/137/2013 Cell A/Massachusetts/15/2013 Cell A/Pennsylvania/07/2013 Cell A/Brisbane/205/2013 Cell A/Singapore/GP1796/2013 Cell A/Wakayama/153/2013 Cell

7 HI ANTIBODY RESPONSES TO THE A(H1N1)pdm09 COMPONENT (% GMT) relative GMT Egg-ref virus Egg or cell isolates 7

8 A(H1N1)pdm09-summary Vaccines containing A/California/7/2009 antigens elicited anti-HA antibodies of similar geometric mean HI titers to the vaccine virus and the majority of representative A(H1N1)pdm09 viruses 8

9 9 A(H3N2) Serology

10 Antigens for serology: A(H3N2) REFERENCE VIRUS A/Texas/50/2012 egg or cell REPRESENTATIVE CURRENT VIRUSES A/New York/39/2012egg A/New York/39/2012cell A/Utah/07/2013egg A/Utah/07/2013cell A/Almaty/2958/2013Egg A/Massachusetts/11/2013Egg A/Victoria/506/2013Egg A/Jiangxi-Xunyang/1790/2013Cell A/Louisiana/09/2013Cell A/Tokyo/31512/2013Cell =Egg and cell pair

11 HI ANTIBODY RESPONSES TO THE A(H3N2) COMPONENT: using A/Texas/50/2012 egg-grown virus as reference relative GMT Egg-grown ref. Egg-isolates Cell isolates 11

12 HI ANTIBODY RESPONSES TO THE A(H3N2) COMPONENT: using A/Texas/50/2012 cell-grown virus as reference Egg-isolates relative GMT 12 Cell-grown ref Cell-grown ref. Cell isolates

13 A(H3N2)-summary Vaccines containing A/Texas/50/2012 antigens induced anti-HA antibodies of similar geometric mean HI titers (GMT) to recent egg-propagated A(H3N2) viruses as to the vaccine virus. Reduced GMTs were observed for some recent cell- propagated viruses when compared to titers to the egg-propagated vaccine viruses. 13

14 14 Influenza B Serology

15 Antigens for serology: influenza B REFERENCE VIRUSES B/Massachusetts/2/2012 egg and cell (Yam) B/Brisbane/60/2008 egg (Vic, quadrivalent vaccine only) REPRESENTATIVE CURRENT VIRUSES Yamagata lineage B/Arizona/8/2013Cell B/Chongqing-Yuzhong/11616/2013Egg B/Lithuania/6935/2013Cell B/Shandong-Mudan/1374/2013Cell B/Guatemala/8/2013Cell B/Hong Kong/315/2013Cell B/Phuket/3073/2013Egg B/Townsville/15/2013Cell B/Osaka/18/2013Cell Victoria lineage B/Brisbane/60/2008Egg B/Texas/2/2013Egg B/Texas/2/2013Cell B/Ghana/1118/2013Cell B/Jiangsu-Tianning/1796/2013egg

16 relative GMT 16 Yam-like isolates Vic-like isolates All Yam-like isolates All Vic-like isolates HI ANTIBODY RESPONSES TO THE B-Yam COMPONENT (% GMT)

17 relative GMT 17 HI ANTIBODY RESPONSES TO THE B-Vic COMPONENT of QUADRIVALENT VACCINHE (% GMT)

18 B-summary Vaccines containing B/Massachusetts/2/2012 (Yam) antigen elicited anti-HA antibodies of similar geometric mean titers to the vaccine virus and the majority of representative recent Yam-lineage viruses, and as expected,elicited anti-HA antibodies of lower titers to representative recent Vic-lineage viruses. Vaccines containing B/Massachusetts/2/2012 and B/Brisbane/60/2008 (Vic) antigens elicited anti-HA antibodies of similar geometric mean titres to the vaccine viruses and the majority of representative recent Yam- and the Vic-lineage viruses. 18

19 Summary l H1N1pdm09 –Vaccines containing A/California/7/2009-like antigens stimulated anti-HA antibodies of geometric mean titers to representative recent A(H1N1)pdm09 viruses that were not significantly reduced as compared to titers against A/California/7/2009-like reference viruses l H3N2 –Vaccines containing A/Texas/50/2012 antigens induced anti-HA antibodies of similar geometric mean HI titers (GMT) to the recent egg-propagated A(H3N2) viruses, but lower GMTs to some recent cell-propagated viruses, when compared to the egg-propagated vaccine viruses. l B –Vaccines containing B/Massachusetts/2/2012 (Yam) antigen elicited anti-HA antibodies of similar geometric mean titers to the vaccine virus and the majority of representative recent Yam-lineage viruses, and elicited the antibodies of low titers to the representative recent Vic-lineage viruses. –Vaccines containing B/Massachusetts/2/2012 and B/Brisbane/60/2008 (Vic) antigens elicited anti-HA antibodies of similar geometric mean titers to the vaccine viruses and the majority of representative recent Yam- and the Vic-lineage viruses. 19

Download ppt "Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory."

Similar presentations

Candidate Vaccine Strains and Potency Reagents for Influenza Season

Candidate Vaccine Strains and Potency Reagents for Influenza Season
Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.
Influenza Vaccine Manufacturing

Influenza Vaccine Manufacturing
Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.
INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA (Seasonal Influenza and Zoonotic Influenza) FEBRUARY 28, 2012.

INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA (Seasonal Influenza and Zoonotic Influenza) FEBRUARY 28, 2012.
Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.
INFLUENZA VACCINE CONSIDERATIONS 2014-2015 SEASON Alicia Vanden Bosch, PharmD Creighton University SPAHP September, 2014 1.

INFLUENZA VACCINE CONSIDERATIONS SEASON Alicia Vanden Bosch, PharmD Creighton University SPAHP September,
Tonya Philbrick, BS, NCMA Director

Tonya Philbrick, BS, NCMA Director
Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
CAF01 adjuvant increases the protection conferred by a commercially available influenza split vaccine in a ferret model Introduction Desirable traits of.

CAF01 adjuvant increases the protection conferred by a commercially available influenza split vaccine in a ferret model Introduction Desirable traits of.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.
Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.
Influenza Vaccine Manufacturing Industry perspective for 2013-2014 influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.
Influenza Timothy Wiemken, PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville

Influenza Timothy Wiemken, PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville
Influenza Virus Vaccine 2013-2014 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.
Influenza Virus Vaccine 2014-2015 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.
INFLUENZA VACCINE Group 1 Zainab Ashfaq Bushra Abbas Ahtasham Danish.

INFLUENZA VACCINE Group 1 Zainab Ashfaq Bushra Abbas Ahtasham Danish.

Similar presentations

Ads by Google